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 Introduction 
 Osteoporosis is a disease characterised by low bone mass, defined 
by the World Health Organization as equalling or exceeding 2.5 
standard deviations below the mean for healthy young adult 
women at any site, and is associated with increased susceptibility 
to fragility fractures. 1,2 Osteoporotic fractures cause substantial 
morbidity, mortality and health economic cost, with hip fractures 
in particular resulting in a 1-year mortality of 20% and permanent 
disability in up to 50% of cases. 2 Incidence of hip fracture is 
projected to exceed 100,000 UK cases per year by 2020 as the 
population ages, with direct health costs alone exceeding £2 billion 
per annum. 3 
 Given this context, identifying those at an increased risk 
of fracture and targeting effective interventions to the right 
individuals is a major public health concern. The National 
Institute for Health and Care Excellence (NICE) advises assessing 
fracture risk in all women over the age of 65 years and men over 
the age of 75 years, as well as younger individuals with other 
known bone health risk factors, using a fracture risk assessment 
tool, such as FRAX or QFracture, in the first instance. 2 Dual 
energy X-ray absorptiometry (DEXA) scanning should then be 
considered for: those individuals whose fracture risk is close to 
a treatment intervention threshold, people over the age of 50 
who have sustained a fragility fracture, those being commenced 
on treatments known to have rapid effects on bone density like 
aromatase inhibitors, or individuals under the age of 40 with a 
major bone health risk factor. 2 The International Society for Clinical 
Densitometry (ISCD) recommends similar, though not identical, 
indications for DEXA scanning. 4 
 The Royal National Hospital for Rheumatic Diseases (RNHRD), 
Bath, offers a direct access requesting and reporting service for 
DEXA scans to local primary and secondary care clinicians, in order 
to facilitate identification of individuals at increased risk of future 
fragility fractures. The DEXA reports quote a post-DEXA FRAX 
risk score where possible and include an individualised treatment 
recommendation. The latter is based on locally agreed intervention 
thresholds, which differ from National Osteoporosis Guideline 
Group (NOGG) recommendations most significantly in that a 
fixed intervention threshold (treatment advised if 10-year major 
osteoporotic fracture risk exceeds 20% or hip fracture risk exceeds 
5%) is used across all ages, rather than being age-dependent. 
 In addition to those indications for DEXA scanning recommended 
by NICE and ISCD, DEXA scans are also performed when requested 
due to an ‘osteopaenic appearance’ being reported on plain X-ray 
or other imaging modality. Our aim was to identify the extent 
to which performing a DEXA for this indication alone affected 
treatment recommendations. 
 Methods 
 A retrospective analysis was performed of DEXA reports issued 
by RNHRD between 1 October 2016 and 30 September 2018. 
Reporters included two consultant rheumatologists, with a 
specialist nurse and several rheumatology specialist registrars also 
reporting with consultant support. 
 An initial search was performed of the RNHRD clinical 
measurement department database in order to identify DEXA 
scans which were requested with ‘osteopaenic X-ray appearance’ 
being offered as the sole indication. A further review was then 
performed for each patient of their bone health risk factors in order 
to identify whether the DEXA could in any case have been justified 
according to current NICE or ISCD guidelines. Patients were 
excluded from further analysis if an alternative DEXA indication to 
‘osteopaenic X-ray appearance’ was identified at this review. 
 For the remaining patients, a pre-DEXA FRAX risk score was 
calculated with the consequent NOGG recommendation 
recorded. The DEXA reports for these patients were then analysed 
with the following parameters recorded: age; site of reported 
osteopaenia (further categorised as axial if vertebral or pelvic, 
versus peripheral if elsewhere); bone mineral density (BMD) 
category (osteoporosis, osteopaenia or normal BMD); treatment 
and follow up recommended by the reporter; whether treatment 
recommendation strictly adhered to local guidelines; and whether 
treatment would be recommended according to NOGG. We 
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2019 ]. then identified those cases where the treatment or follow-up 
recommendation changed as a result of the DEXA, for example 
where the DEXA report recommended bisphosphonate treatment 
whereas NOGG would have recommended reassurance and 
lifestyle measures based on the pre-DEXA FRAX score. 
 Results and discussion 
 Ninety-one patients were identified by the initial database search 
as having been referred for DEXA on the basis of ‘osteopaenic 
X-ray appearance’. Overall, bisphosphonate treatment was 
recommended in 20 of these patients (22%) and a follow-up DEXA 
was recommended in 22 patients (24%). 
 Following the subsequent review, we identified that 71 of these 
could have been justified by existing NICE and/or ISCD guidance, 
hence were excluded from further analysis (reasons for exclusion 
detailed in Table  1 ). 
 Of the remaining 20 patients who underwent a DEXA scan in 
this time period (ie those performed for the sole indication of 
an osteopaenic X-ray appearance), three were found to have 
osteoporosis, 10 had osteopaenia and seven had normal bone 
mineral density. In one (5%) case a recommendation was made to 
treat with a bisphosphonate, on a patient where osteopenia was 
reported on an ankle X-ray, who was found to be osteoporotic by 
BMD. A follow-up DEXA was recommended for two patients in total 
(10%). All other patients in this cohort were recommended bone 
health lifestyle measures only. In this cohort of patients, there were 
no discrepancies between the actual treatment recommended in 
the report with both local and NOGG recommendations, based on 
the post-DEXA FRAX score. 
 Conclusion 
 This analysis demonstrates that offering DEXA scanning to 
patients with an osteopaenic X-ray appearance who would not 
otherwise meet NICE criteria for this test may allow identification 
of a small number of additional individuals who could benefit 
from antiresorptive treatment and/or monitoring of bone density. 
Whether this is sufficient to justify the additional resource utilised 
remains open for debate. The major limitations of this analysis are 
its retrospective nature, small cohort numbers and dependence 
on internal coding of the indication for a DEXA request to identify 
patients. Future work could include a prospective cohort analysis 
of the bone health of patients found to have an osteopaenic X-ray 
appearance. ■ 
 Table 1.  Patients excluded from further analysis due 
to alternative indication for DEXA 
Alternative indication for DEXA N 
Pre-DEXA FRAX score results in NOGG recommendation for 
DEXA
36
History of fragility fracture 25
Secondary causes of osteoporosis, not adequately captured 
by FRAX
6
Follow up after a previous DEXA 2
Osteopaenic X-ray report couldn't be identified 2
 DEXA = dual energy X-ray absorptiometry; FRAX = a tool to evaluate fracture 
risk in patients; NOGG = National Osteoporosis Guideline Group. 
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